These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Tysabri raises alarm bells on drug class. Sheridan C Nat Biotechnol; 2005 Apr; 23(4):397-8. PubMed ID: 15815649 [No Abstract] [Full Text] [Related]
11. Lessons for clinical trials from natalizumab in multiple sclerosis. Chaudhuri A BMJ; 2006 Feb; 332(7538):416-9. PubMed ID: 16484271 [TBL] [Abstract][Full Text] [Related]
12. Third Tysabri adverse case hits drug class. Sheridan C Nat Rev Drug Discov; 2005 May; 4(5):357-8. PubMed ID: 15902765 [No Abstract] [Full Text] [Related]
13. Balancing risk and reward: the question of natalizumab. Hauser SL; Johnston SC Ann Neurol; 2009 Sep; 66(3):A7-8. PubMed ID: 19810091 [No Abstract] [Full Text] [Related]
14. Tysabri withdrawal calls entire class into question. Singer E Nat Med; 2005 Apr; 11(4):359. PubMed ID: 15812500 [No Abstract] [Full Text] [Related]
19. Does the flap of a butterfly's wings in Brazil set off a tornado in Texas?--The JC Virus Story in multiple sclerosis. Achiron A; Miron S; Shoenfeld Y Isr Med Assoc J; 2005 May; 7(5):283-5. PubMed ID: 15909458 [No Abstract] [Full Text] [Related]
20. Natalizumab and PML: a risky business? Clifford DB Gut; 2008 Oct; 57(10):1347-9. PubMed ID: 18791114 [No Abstract] [Full Text] [Related] [Next] [New Search]